The UK Vaccine Network brings together industry, academia and relevant funding bodies to make targeted investments in specific vaccines and vaccine technology for infectious diseases with the potential to cause an epidemic.
Role of the group
Vaccines are widely recognised as an important mechanism in controlling infectious disease outbreaks. However, outbreaks of some of the world’s deadliest diseases only occur intermittently, and often in the world’s poorest countries, meaning that there may not be a strong market incentive to for the pharmaceutical industry to develop vaccines for such diseases.
The UK government is taking concerted and coordinated action to address this market failure. The UK has committed to invest £120 million between 2016 and 2021 for the development of new vaccines for such diseases, in line with the expert advice provided by the UK Vaccines Network.
The focus of the Network is to support the government to identify and shortlist targeted investment opportunities for the most promising vaccines and vaccine technologies that will help combat infectious diseases with epidemic potential, and to address structural issues related to the UK’s broader vaccine infrastructure.
The UK Vaccine Network is made up of leading experts from academia, industry and policy. All members are invited to join the Network in a personal capacity, not as representatives of specific organisations or bodies.
Chris Whitty, Chief Scientific Adviser to the Department of Health and Social Care
- Adrian Hill
- Andrew Pollard
- Bryan Charleston
- Ceri Lyn-Adams
- Charlie Weller
- Charlotte Watts
- Chris Whitty
- Christian Schneider
- Eleanor Riley
- Fiona Tomley
- Gary Entrican
- Ian Hudson
- Jean Lang
- Jeffrey Almond
- Joann Prior
- Johan Van Hoof
- John Edmunds
- Jonathan Pearce
- Julian Bonnerjea
- Mahesh Kumar
- Massimo Pamlarini
- Mike Francis
- Miles Carroll
- Neil Ferguson
- Nick Adkin
- Paul Cosford,
- Peter Openshaw
- Simon Foster
- Stephen Inglis
- Steve Chatfield
- Sue Middleton
- Tarit Mukhopadhyay
- Timothy Atkins
- Xiao-Ning Xu
The Vaccine Network operates through a series of working groups. Each group has a specific focus and they feedback their findings to the Network. A full list of contributors for each working group is listed at the bottom of this page.
Working group 1: Identify and prioritise human and zoonotic diseases
Chair: Miles Carrol, Public Health England.
Working group 1 identifies and prioritises human and zoonotic diseases with epidemic potential in human or animal populations, for which vaccines can have an outbreak altering impact. The group also looks for gaps in knowledge about these diseases (including basic pathogen biology and host immunology), and where human and veterinary vaccinology can learn from each other. The group’s findings are used to inform the investment strategy for the £120 million budget.
The pathogens for which investment in vaccine development was identified as a priority by the UK Vaccine Network are:
- Chikungunya virus
- Crimean Congo Haemorrhagic Fever (CCHF) virus
- Ebola virus
- Lassa Fever virus
- Marburg virus
- Middle Eastern Respiratory Syndrome (MERS) virus
- Nipah virus
- Plague (Yersinia pestis)
- Q fever (Coxiella burnetii)
- Rift Valley Fever virus
- Zika virus
Working group 2: Understand how a vaccine will impact on an epidemic disease outbreak
Chair: Eleanor Riley, The Roslin Institute.
Working group 2 aims to develop a systematic, shared understanding of under what circumstances a vaccine is likely or unlikely to have an impact on an epidemic disease outbreak. This includes outbreaks where the pathogen is not currently known, and what vaccine technologies could play an important role in future outbreaks. The group has created a decision tool based on this work.
Working group 3: Produce a process map for vaccine development, from discovery to deployment
Chair: Tarit Mukhopadhyay, University College London.
Working group 3 produces process maps for vaccine discovery, development, manufacture and deployment. These will help to understand where the main rate limiting steps are for any given vaccine and mean that these can be addressed efficiently. See the process maps.
Working group 4: Look at the manufacture of vaccines
Chair: Jeffrey Almond, University of Oxford.
Working group 4 considers questions around the manufacture of vaccines, such as:
- where could a small scale or large scale facility make a difference in the UK?
- what could we build, and where/with whom could or should we collaborate with?
- what existing facilities are there that could support scale-up for manufacture of small stockpiles?
The Department of Health and Social Care is funding a number of projects to develop candidate vaccines for priority pathogens and to develop technologies and processes to support vaccine manufacturing and delivery in low and middle income countries (LMICs). A total of over £71 million has been committed to date.
The following table shows a summary of the research competitions held to identify successful projects. The attachment below the table has further information about individual projects. In addition, in 2016, £2.95 million of the Network’s budget was used to make a one-off donation to the PATH product development partnership.
|Delivery partner||Competition theme||Funding provided|
|Innovate UK||Vaccine Development Competition 24 projects supported over 3 competition strands: pre-clinical clinical; and second stage competition to further support successful pre-clinical projects||£18,598,036|
|Preclinical Vaccine Development Competition 22 projects supported in the first stage. A second stage competition will offer further support to successful projects||£9,621,879|
|Clinical Vaccine Development Competition – 7 projects supported, all including clinical stage work||£21,340,452|
|National Institute for Health Research (NIHR)||Medical Research Council / Biotechnology and Biological Sciences Research Council (BBSRC) Intramural Centre led projects – 6 projects funded to support late pre-clinical research and early clinical development of vaccine candidates||£12,027,347|
|Engineering and Physical Sciences Research Council (EPSRC)||Centre for Innovative Vaccine Manufacturing – grant awarded to develop a collaborative vaccine manufacturing hub||£9,947,570|
|NIHR||Epidemiology for Vaccinology Competition – one large grant and a number of smaller grants to support development of epidemiological models, tools and technologies for use during outbreaks||About £5 million (not yet allocated)|
|BBSRC||‘One-Health’ Vaccinology Competition – number of smaller grants to support antigen discovery and disease understanding for viral and bacterial families that impact on animal and human health in LMICs.||About £5 million (not yet allocated)|
Working group contributors
|Working Group 1||Working Group 2||Working Group 3||Working Group 4|
|Adrian Hill||Adrian Hill||Adrian Hill||Adrian Hill|
|Andrew Simpson||Brendan Wren||Brendan Wren||Andrew Hopkins|
|Beata Kampmann||Bryan Charleston||Charlie Weller||Bassam Hallis|
|Bryan Charleston||Chris Whitty||Chris Whitty||Calman MacLennan|
|Chris Whitty||Dirk Pfeiffer||Diane Williams||Catriona Crombie|
|Elisabeth Innes||Eleanor Riley||James Wood||Charlie Weller|
|Gary Entrican||Fiona Tomley||Jeffrey Almond||Chris Whitty|
|Gordon Dougan||John Fazakerley||Jeremy Salt||David Churchward|
|Ivan Morrison||Jon Cuccui||Jonathan Rushton||David Griffiths-Johnson|
|Joann Prior||Jonathan Pearce||Mahesh Kumar||Ian Rees|
|John Edmunds||Mahesh Kumar||Mark Carver||Jeffrey Almond (Chair)|
|Jonathan Pearce||Mary Collins||Matthew Downham||Jon Mowles|
|Josie Golding||Mike Turner||Mike Francis||Michael Watson|
|Margaret Hosie||Neil Ferguson||Mike Udell||Mike Murray|
|Mark Stevens||Nigel Silman||Miles Carroll||Miles Carroll|
|Massimo Pamlarini||Rob Field||Nigel Silman||Neil Baker|
|Mike Francis||Nilay Shah||Nigel Titchener-Hooker|
|Miles Carroll (Chair)||Niranjan Kanesa Thasan||Nilay Shah|
|Neil Ferguson||Niranjan Kanesa-Thasan||Niranjan Kanesa Thasan|
|Nigel Silman||Rachel Smith||Peter Large|
|Rob Noad||Rino Rappuoli||Peter McCormack|
|Roger Hewson||Sarah Gilbert||Phil Sizer|
|Sandra Adams||Simon Foster||Richard Alldread|
|Sarah Gilbert||Stephen Inglis||Richard Hebdon|
|Sarah Plowman||Steve Carleysmith||Sarah Gilbert|
|Tony Fooks||Steve Chatfield||Stephen Inglis|
|Xiao-Ning Xu||Tarit Mukhopadhyay (Chair)||Steve Chatfield|
|Adrian Hill||Xiao-Ning Xu||Subhash Chaudhary|
|Andrew Simpson||Tarit Mukhopadhyay|
|Beata Kampmann||Tony Hitchcock|
|Bryan Charleston||Virginia Acha|